Mevrometostat plus enzalutamide in metastatic castration-resistant

Phase 3 mCRPC trial adding EZH2 inhibitor mevrometostat to enzalutamide in ARSi/abiraterone-naive patients. While preclinical rationale exists, EZH2 inhibitors have limited clinical validation in prostate cancer, and Phase 3 oncology success rates are ~35-40%. No strong Phase 2 data publicly available; risk of failure is significant.

EZH2 inhibitor mevrometostat has plausible biology in mCRPC but EZH2 inhibitors have limited clinical success in solid tumors. Adding to enzalutamide in ARSi-naive patients requires meaningful incremental rPFS benefit. Phase 3 oncology trials historically succeed ~35-40% and novel epigenetic targets face higher hurdles. Trial execution by Pfizer is solid but mechanism risk keeps probability below 0.5.

Pfizer's mevrometostat targets LSD1, a mechanism with strong preclinical rationale in AR-driven prostate cancer. Phase 3 design combines it with enzalutamide in ARSi-naive mCRPC, a population likely to respond. While LSD1 inhibitors have faced toxicity hurdles, Pfizer's optimization may mitigate this. rPFS is a standard, achievable endpoint. However, lack of prior Phase 2 efficacy data in this specific setting introduces uncertainty.

Phase 3 mCRPC trial is still recruiting with no efficacy data. The investigational epigenetic agent mevrometostat is unproven in this setting, and adding it to enzalutamide must improve rPFS against a strong standard. Historical Phase 3 oncology combo success rates are modest, suggesting a low intrinsic chance of meeting the rPFS endpoint.

Phase 3 rPFS in ARSI-naive mCRPC is a high bar; enzalutamide control is active and prior novel combinations in this setting have high failure rates. EZH2 inhibition has preclinical rationale but limited published Phase 2 rPFS data to de-risk the combo. Pfizer execution is solid, but 161 days to completion with no disclosure suggests blinded ongoing recruitment and outcome uncertainty. Base rate for Phase 3 novel oncology mechanisms supports sub-50% odds.

Phase 3 mCRPC study combining EZH2 inhibitor mevrometostat with enzalutamide in ARSi/abiraterone-naive patients. EZH2 inhibitors have mixed track record across cancers; similar targeted combinations in mCRPC have frequently failed in Phase 3. Naive population is favorable, but novel mechanism synergy with enzalutamide is unproven. Pfizer sponsorship reduces execution risk but doesn't guarantee efficacy. rPFS endpoint is objective. Intrinsic YES odds around 35% given high failure rates in late-stage prostate cancer combinations.